文献速递临床试验与 GCP流行病学与生物统计

荷兰急性缺血性卒中血管内治疗多中心随机临床试验(MR CLEAN)的两年临床随访:扩展随访研究的设计与统计分析计划

Two-year clinical follow-up of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands (MR CLEAN): design and statistical analysis plan of the extended follow-up study.
PubMed 文献 · Trials · 2016-11-22

MR CLEAN是第一项证明血管内治疗对大血管闭塞所致急性缺血性卒中短期有效的随机试验,但长期结局数据有限。本研究将随访从3个月延长至2年,评估血管内治疗对两年时改良Rankin量表评分、全因死亡及主要血管事件的影响。

要点

  • MR CLEAN将随访从3个月延长至2年,评估血管内治疗的长期临床效果。
  • 主要结局为两年时改良Rankin量表评分,次要结局包括全因死亡和主要血管事件。
  • 纳入标准为18岁及以上、前循环近端动脉闭塞、发病6小时内可治疗的患者。

核心结论

  • 本研究结果提供血管内治疗长期临床有效性的信息,可能对个体治疗决策和成本效果估计产生影响。

研究设计与样本

  • MR CLEAN为多中心临床试验,采用随机治疗分配、开放标签治疗和盲法终点评估。
  • 纳入18岁及以上、经证实的前循环近端动脉闭塞所致急性缺血性卒中、发病6小时内可治疗的患者。
  • 干预对比为血管内治疗联合常规护理 versus 无血管内治疗联合常规护理。
  • 本研究将随访时间从3个月延长至2年。

主要发现

  • 主要结局为两年时改良Rankin量表评分。
  • 次要结局包括随访两年内的全因死亡和主要血管事件发生。

关键数值与推荐

  • 主要结局指标:两年时改良Rankin量表评分。
  • 次要结局指标:随访两年内全因死亡和主要血管事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MR CLEAN was the first randomized trial to demonstrate the short-term clinical effectiveness of endovascular treatment in patients with acute ischemic stroke caused by large vessel occlusion in the anterior circulation. Several other trials confirmed that endovascular treatment improves clinical outcome at three months. However, limited data are available on long-term clinical outcome. We aimed to estimate the effect of endovascular treatment on functional outcome at two-year follow-up in patients with acute ischemic stroke. Secondly, we aimed to assess the effect of endovascular treatment on major vascular events and mortality during two years of follow-up. METHODS: MR CLEAN is a multicenter clinical trial with randomized treatment allocation, open-label treatment, and blinded endpoint evaluation. Patients included were 18 years or older with acute ischemic stroke caused by a proven anterior proximal artery occlusion who could be treated within six hours after stroke onset. The intervention contrast was endovascular treatment and usual care versus no endovascular treatment and usual care. The current study extended the follow-up duration from three months to two years. The primary outcome is the score on the modified Rankin scale at two years. Secondary outcomes include all-cause mortality and the occurrence of major vascular events within two years of follow-up. DISCUSSION: The results of our study provide information on the long-term clinical effectiveness of endovascular treatment, which may have implications for individual treatment decisions and estimates of cost-effectiveness. TRIAL REGISTRATION: NTR1804 . Registered on 7 May 2009; ISRCTN10888758 . Registered on 24 July 2012 (main MR CLEAN trial); NTR5073 . Registered on 26 February 2015 (extended follow-up study).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van den Berg LA, Dijkgraaf MG, Berkhemer OA, et al. Two-year clinical follow-up of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands (MR CLEAN): design and statistical analysis plan of the extended follow-up study. Trials. 2016. PMID: 27876083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。